Abstract | PURPOSE: METHODS: In vitro crosslinking assays, [14C] scintillation counting analyses and alkaline comet assays were applied to characterize pixantrone- DNA adducts. Flow cytometry, cell growth inhibition and clonogenic assays were used to measure cancer cell kill and survival. RESULTS: CONCLUSIONS: The features unique to pixantrone- DNA adducts may be leveraged to enhance cancer cell kill and may be used to guide the design of pixantrone analogues that generate adducts with more favorable anticancer properties.
|
Authors | Oula C Mansour, Abraham Nudelman, Ada Rephaeli, Don R Phillips, Suzanne M Cutts, Benny J Evison |
Journal | Cancer chemotherapy and pharmacology
(Cancer Chemother Pharmacol)
Vol. 89
Issue 6
Pg. 773-784
(06 2022)
ISSN: 1432-0843 [Electronic] Germany |
PMID | 35460360
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
|
Copyright | © 2022. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature. |
Chemical References |
- DNA Adducts
- Isoquinolines
- Prodrugs
- Formaldehyde
- DNA Topoisomerases, Type II
- pixantrone
|
Topics |
- DNA Adducts
- DNA Topoisomerases, Type II
(metabolism)
- Formaldehyde
(pharmacology)
- Humans
- Isoquinolines
- Neoplasms
- Prodrugs
(pharmacology)
|